IMRX

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Immuneering Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Immuneering Corp. EPS for the last quarter amounts to -0.38 USD, decreased -22.45 % YoY.

Immuneering Corp (IMRX) has 66 emplpoyees as of December 16 2025.

Today IMRX has the market capitalization of 373.21M USD.